Oncolytic Virus Cancer Therapy Pipeline Appears Robust With 120+ Key Pharma Companies Actively Working

Strategic Insights -

The Oncolytic Virus Cancer Therapy pipeline has emerged as a significant area of focus for pharmaceutical companies, with over 120 key players actively working on developing therapies for the treatment of various cancer types. DelveInsight's report, "Oncolytic Virus Cancer Therapy Pipeline Insight, 2025," provides comprehensive insights into the pipeline landscape, highlighting the growing interest in this therapeutics segment. The report covers a wide range of therapeutic candidates, including Olvi-Vec, CAN-2409, CG0070, and Pelareorep, among others.

Key Takeaways:

  • The Oncolytic Virus Cancer Therapy pipeline report provides a detailed analysis of the pipeline landscape, covering over 120 companies and 125+ pipeline drugs.
  • The report highlights the diverse range of therapeutic candidates, including Olvi-Vec, CAN-2409, CG0070, and Pelareorep, among others.
  • Notable companies involved in the development of Oncolytic Virus Cancer Therapy include Genelux Corporation, Candel Therapeutics, CG Oncolgy, DNAtrix, and SillaJen Biotherapeutics.
  • The pipeline report not only emphasizes the therapeutic candidates but also discusses the unmet needs and market drivers and barriers in the Oncolytic Virus Cancer Therapy market.
  • The report is a valuable resource for companies, academia, and Institutes seeking to advance their understanding of the Oncolytic Virus Cancer Therapy pipeline and its potential impact on the cancer treatment landscape.

Statistics:

  • The Oncolytic Virus Cancer Therapy pipeline report covers over 120 companies and 125+ pipeline drugs.
  • Notable companies involved in the development of Oncolytic Virus Cancer Therapy include Genelux Corporation, Candel Therapeutics, CG Oncolgy, DNAtrix, and SillaJen Biotherapeutics.
  • The pipeline report highlights the diverse range of therapeutic candidates, including Olvi-Vec, CAN-2409, CG0070, and Pelareorep, among others.

Sources:

  • "Oncolytic Virus Cancer Therapy Pipeline Insight, 2025," Report by DelveInsight.
  • M2 PressWIRE, July 16, 2025.
  • DelveInsight's "Oncolytic Virus Cancer Therapy Pipeline Landscape report."